Copyright
©The Author(s) 2019.
World J Gastroenterol. Aug 21, 2019; 25(31): 4481-4492
Published online Aug 21, 2019. doi: 10.3748/wjg.v25.i31.4481
Published online Aug 21, 2019. doi: 10.3748/wjg.v25.i31.4481
Parameter | OR | 95%CI | P value |
Male sex | 0.112 | (0.021; 0.605) | 0.011 |
Extraintestinal manifestations | 0.119 | (0.022; 0.636) | 0.013 |
HBI at baseline | 0.853 | (0.718; 1.014) | 0.071 |
Use of steroids (including budesonide) at baseline | 0.071 | (0.011; 0.464) | 0.006 |
- Citation: Hoffmann P, Krisam J, Wehling C, Kloeters-Plachky P, Leopold Y, Belling N, Gauss A. Ustekinumab: “Real-world” outcomes and potential predictors of nonresponse in treatment-refractory Crohn’s disease. World J Gastroenterol 2019; 25(31): 4481-4492
- URL: https://www.wjgnet.com/1007-9327/full/v25/i31/4481.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i31.4481